CLAIM CARD
The evidence profile indicates that the current evidence supports metformin's role in glycemic management and suggests possible secondary benefits for colorectal neoplasia prevention and sepsis prognosis, but the anti-aging and cardioprotective case as currently constituted remains incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions under which net benefit accrues have yet to be is consistent with.
Evidence grade: exploratory
Contradiction status: none
Publication: 5f566366-fb20-4402-ba24-c1117573f97f
Provenance: Derivation Web chain
Citation Support
source_1Zaveri 2026source_2Wu 2026source_3Hong 2026source_4Lee 2026source_5Seo 2026